Raphael (Rafi) Hofstein

CML HealthCare Inc. and MaRS Innovation Enter into Strategic Partnership

September 23, 2012
Susanne Staer
Industry Partners

MISSISSAUGA, Ontario, September 18, 2012 – CML HealthCare Inc. (TSX: CLC) (the “Company” or “CML”) and MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in medical diagnostics.

This story was covered in the Globe and Mail, Canadian Business, 680 News, Reuters, Sympatico.ca, the Huffington Post Canada, Technology Trasnfer Tactics, and the Winnipeg Free Press, among others. It was distributed via Yahoo! Finance, Healthcare Global.com, marketwire and Digital Journal.

Huffington Post Canada interviews Raphael Hofstein about Canadian venture capital shortage

August 20, 2012
Susanne Staer
Media Coverage

Raphael Hofstein, president and CEO of MaRS Innovation, was interviewed by Huffington Post Canada business reporter Rachel Mendleson for an article about Canada’s innovation gap and the shortage of Canadian venture capital:

One of the best ways to [raise venture capital], said Raphael Hofstein, President and CEO of Toronto-based MaRS Innovation, is to increase government investment, a lesson he learned while helping to create a life sciences early-stage fund in Israel several years ago.

“Everybody told us — institutions, industry — that they will not participate unless government has a piece of the pie. So governments have to participate, certainly in the early stage,” he said.

BioCentury Features Xagenic’s PCR-Based Infection-Diagnosis Technology

Xagenic, a MaRS Innovation spin-off company, was featured in the most recent issue of BioCentury. Here's an excerpt (the article only available to BioCentury subscribers): PCR-based diagnosis of infections can…

MaRS Innovation’s Lead Start-Up Completes $20 Million Series B

Xagenic’s financing round to test platform and first diagnostic assay, continue product development and begin FDA submission Toronto, ON (December 2, 2013) — MaRS Innovation’s first start-up company, Xagenic Inc.,…

Business Without Borders features Encycle Therapeutics, Raphael Hofstein

Encycle Therapeutics, a MaRS Innovation spin-off company, was featured by Business Without Borders' High Tech section in a Q&A profile with MI's President and CEO, Raphael Hofstein. Here's an excerpt:…

Raphael Hofstein’s editorial in National Post’s Medical Devices supplement

MaRS Innovation's President and CEO, Raphael Hofstein, has published an editorial outlining the challenges facing entrepreneurs seeking to bring new healthcare innovations to market for the National Post's Medical Devices…

Montreal’s La Presse covers life science research funding project among MI, CQDM, OCE and OBI

This week, MaRS Innovation (MI) announced a new partnership agreement with The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute (OBI) and Ontario Centres of Excellence (OCE) to launch the Québec/Ontario CQDM Funding Program.

The funding program will support collaborative life science research projects between the two provinces that seek to develop new tools for biopharmaceutical research.

Raphael Hofstein’s guest blog for the Ontario Ministry of Economic Development and Innovation

At the 2012 BIO International Convention in Boston this week, MaRS Innovation, The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute and the Ontario Centres of Excellence announced we are launching a new life sciences funding program within the Ontario-Québec Corridor.

The Ontario-Québec Life Sciences Corridor was itself announced at the 2011 BIO International Convention. Shortly thereafter, Max Felhmann, president and CEO of CQDM, and Raphael Hofstein, president and CEO of MaRS Innovation, decided to collaborate on a joint pilot project, which has produced Encycle Therapeutics.

CQDM Partners with MaRS Innovation, Ontario Brain Institute and Ontario Centres of Excellence to Launch Life Sciences Funding Program Within Ontario-Québec Corridor

BOSTON, MA, June 18, 2012 — Together with key partners from Ontario, The Québec Consortium for Drug Discovery (CQDM) is creating a new initiative to fund collaborative life sciences research projects between the two provinces.

A French version of this release is available via CQDM’s website.

This initiative is the first notable and concrete realization of the Ontario-Québec Life Sciences Corridor, announced at the 2011 BIO International Convention. It builds upon two previous pilot projects and existing strengths within the two provinces to increase innovation, productivity, investment and job creation.

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

Platform for cyclizing peptides promises to increase efficiency of early-stage drug discovery

BOSTON, June 18, 2012 – Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process.

Peptides have long been sought after as therapeutics due to their high specificity — they can hit specific cellular targets, especially complex protein-protein interaction targets implicated in cancer, cardiovascular disease and metabolic disorders.

CML HealthCare Inc. and MaRS Innovation Enter into Strategic Partnership

Huffington Post Canada interviews Raphael Hofstein about Canadian venture capital shortage

BioCentury Features Xagenic’s PCR-Based Infection-Diagnosis Technology

MaRS Innovation’s Lead Start-Up Completes $20 Million Series B

Business Without Borders features Encycle Therapeutics, Raphael Hofstein

Raphael Hofstein’s editorial in National Post’s Medical Devices supplement

Montreal’s La Presse covers life science research funding project among MI, CQDM, OCE and OBI

Raphael Hofstein’s guest blog for the Ontario Ministry of Economic Development and Innovation

CQDM Partners with MaRS Innovation, Ontario Brain Institute and Ontario Centres of Excellence to Launch Life Sciences Funding Program Within Ontario-Québec Corridor

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

Quick Links

Contact Us